Belgian diagnostics company MDxHealth SA has appointed Michael K. Brawer, MD as Chief Medical Officer to prepare the company for growth in H2/17 and beyond. The urologist and former professor of urology and pathology has over 25 years of experience in the industry leading clinical affairs in urology for diagnostic and pharmaceutical companies. Before joining MDx Health, Brawer served as Vice President of Medical Affairs, Urology at Myriad Genetics where he led all clinical aspects of development, education and commercialisation of Myriad’s prognostic prostate cancer assay. Prior to that, he held senior positions for GTx Inc, Tokai Pharmaceuticals and Threshold Pharmaceuticals. "Dr. Brawer’s arrival rounds out our 2017 campaign to expand our executive team, alongside our goal to nearly double our US sales force, in preparation for a sustained growth phase", commented Dr. Jan Groen, CEO, MDxHealth.
Bright future for biomanufacturers
BackgroundProgress in process engineering and media optimisation has resulted in significant productivity increases in upstream processing driving transformations at drug developers and CDMOs. At BPI Europe in Amsterdam, companies showed strategies and product launches pinpointing the way towards what could become a new industry paradigm: continuous processing and flexible modular production plants, which both address changed production needs.
Sartorius Real Heroes”
ProductsSmart Tools for Microbiological Quality Control. Because Real Heroes Deserve Only the Best.
Immunooncology: Roche presents blood biomarker test
Latest NewsRoche is trying to offer a solution for patient selection in immunooncology. At the ESMO congress in Madrid, the theranostics company presented a liquid biopsy test that measures the tumour mutational burden in order to predict the probability for response to immunotherapy.
‘Adrenaline’ of the immune system discovered
Latest NewsPortuguese and Swiss scientists have discovered that neurons located at mucosal tissues can immediately detect an infection in the organism, promptly producing a substance that acts as an "adrenaline rush" for immune cells.
MDx Health hires Michael Brawer as CMO
AppointmentsBelgian diagnostics company MDxHealth SA has appointed Michael K. Brawer, MD as Chief Medical Officer to prepare the company for growth in H2/17 and beyond. The urologist and former professor of urology and pathology has over 25 years of experience in the industry leading clinical affairs in urology for diagnostic and pharmaceutical companies. Before joining MDx Health, Brawer served as Vice President of Medical Affairs, Urology at Myriad Genetics where he led all clinical aspects of development, education and commercialisation of Myriad’s prognostic prostate cancer assay. Prior to that, he held senior positions for GTx Inc, Tokai Pharmaceuticals and Threshold Pharmaceuticals. "Dr. Brawer’s arrival rounds out our 2017 campaign to expand our executive team, alongside our goal to nearly double our US sales force, in preparation for a sustained growth phase", commented Dr. Jan Groen, CEO, MDxHealth.
AMAL Therapeutics raises €8m
Latest NewsSwiss cancer vaccine developer AMAL Therapeutics has raised €8m in a Series B round led by existing investor Boehringer Ingelheim Venture Fund, and new investors BioMedPartners and Helsinn Investment Fund.
EU states fuel antimicrobial R&D with €56.5m
Latest NewsSix European states, together with the Wellcome Trust, and South Africa have pledged €56.5m to help develop new antibiotics that break resistance.
Allegro STR Single-use Stirred Tank Bioreactors
ProductsThe Allegro STR bioreactor family combines Palls bioprocess engineering expertise, cell culture know-how and our drive for quality into a series of single-use bioreactors that deliver consistent and scalable cell culture performance across the range.
Smartwatch for patient monitoring
Latest NewsResearchers at the University of Sussex have invented a new algorithm that could revolutionise patient monitoring and activity tracking.
EFSA okays GM bacteria as feed supplement
Latest NewsFrench Ajinomoto Eurolysine SAS, part of the world leading producer of amino acids by fermentation, has received a positive safety assessment from the European Food Safety Authority (EFSA) for use of freeze-dried genetically modified E. coli bacteria as a feedstuff supplement.